<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37493896</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy.</ArticleTitle><Pagination><StartPage>1330</StartPage><EndPage>1346</EndPage><MedlinePgn>1330-1346</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-023-01406-z</ELocationID><Abstract><AbstractText>Pathogenic changes to TAR DNA-binding protein 43 (TDP-43) leading to alteration of its homeostasis are a common feature shared by several progressive neurodegenerative diseases for which there is no effective therapy. Here, we developed Drosophila lines expressing either wild type TDP-43 (WT) or that carrying an Amyotrophic Lateral Sclerosis /Frontotemporal Lobar Degeneration-associating G384C mutation that recapitulate several aspects of the TDP-43 pathology. To identify potential therapeutics for TDP-43-related diseases, we implemented a drug repurposing strategy that involved three consecutive steps. Firstly, we evaluated the improvement of eclosion rate, followed by the assessment of locomotive functions at early and late developmental stages. Through this approach, we successfully identified fingolimod, as a promising candidate for modulating TDP-43 toxicity. Fingolimod exhibited several beneficial effects in both WT and mutant models of TDP-43 pathology, including post-transcriptional reduction of TDP-43 levels, rescue of pupal lethality, and improvement of locomotor dysfunctions. These findings provide compelling evidence for the therapeutic potential of fingolimod in addressing TDP-43 pathology, thereby strengthening the rationale for further investigation and consideration of clinical trials. Furthermore, our study demonstrates the utility of our Drosophila-based screening pipeline in identifying novel therapeutics for TDP-43-related diseases. These findings encourage further scale-up screening endeavors using this platform to discover additional compounds with therapeutic potential for TDP-43 pathology.</AbstractText><CopyrightInformation>&#xa9; 2023. The American Society for Experimental Neurotherapeutics, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lo Piccolo</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Musculoskeletal Science and Translational Research Centre (MSTR), Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umegawachi</LastName><ForeName>Takanari</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeewa</LastName><ForeName>Ranchana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potikanond</LastName><ForeName>Saranyapin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nimlamool</LastName><ForeName>Wutigri</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prachayasittikul</LastName><ForeName>Virapong</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotoh</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Platform Technology Research Unit, Sumitomo Pharma Co., Ltd, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaguchi</LastName><ForeName>Masamitsu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jantrapirom</LastName><ForeName>Salinee</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3111-5658</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. salinee.jan@cmu.ac.th.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Drosophila Centre for Human Diseases and Drug Discovery (DHD), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. salinee.jan@cmu.ac.th.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>G926EC510T</RegistryNumber><NameOfSubstance UI="D000068876">Fingolimod Hydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000589036">TBPH protein, Drosophila</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068876" MajorTopicYN="N">Fingolimod Hydrochloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic Lateral Sclerosis</Keyword><Keyword MajorTopicYN="N">Drosophila Melanogaster</Keyword><Keyword MajorTopicYN="N">Drug Repurposing</Keyword><Keyword MajorTopicYN="N">Fingolimod</Keyword><Keyword MajorTopicYN="N">Frontotemporal Dementia</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37493896</ArticleId><ArticleId IdType="pmc">PMC10480388</ArticleId><ArticleId IdType="doi">10.1007/s13311-023-01406-z</ArticleId><ArticleId IdType="pii">10.1007/s13311-023-01406-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stover CM, Lynch NJ, Hanson SJ, Windbichler M, Gregory SG, Schwaeble WJ. Organization of the MASP2 locus and its expression profile in mouse and rat. Mamm Genome. 2004;15(11):887&#x2013;900. doi: 10.1007/s00335-004-3006-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00335-004-3006-8</ArticleId><ArticleId IdType="pubmed">15672593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, Buratti E, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121(Pt 22):3778&#x2013;3785. doi: 10.1242/jcs.038950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.038950</ArticleId><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010;133(Pt 6):1763&#x2013;1771. doi: 10.1093/brain/awq111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq111</ArticleId><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283(19):13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Funk C, Abou-Ajram C, Hutten S, Funk EBE, Kehlenbach RH, et al. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci Rep. 2018;8(1):7084. doi: 10.1038/s41598-018-25007-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25007-5</ArticleId><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452&#x2013;458. doi: 10.1038/nn.2778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2778</ArticleId><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650&#x2013;655. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, et al. A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2010;107(7):3169&#x2013;3174. doi: 10.1073/pnas.0913602107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0913602107</ArticleId><ArticleId IdType="pmc">PMC2840283</ArticleId><ArticleId IdType="pubmed">20133767</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia Morato J, Hans F, von Zweydorf F, Feederle R, Elsasser SJ, Skodras AA, et al. Sirtuin-1 sensitive lysine-136 acetylation drives phase separation and pathological aggregation of TDP-43. Nat Commun. 2022;13(1):1223. doi: 10.1038/s41467-022-28822-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28822-7</ArticleId><ArticleId IdType="pmc">PMC8907366</ArticleId><ArticleId IdType="pubmed">35264561</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009;106(18):7607&#x2013;7612. doi: 10.1073/pnas.0900688106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900688106</ArticleId><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YT, Kuo PH, Chiang CH, Liang JR, Chen YR, Wang S, et al. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. J Biol Chem. 2013;288(13):9049&#x2013;9057. doi: 10.1074/jbc.M112.438564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.438564</ArticleId><ArticleId IdType="pmc">PMC3610977</ArticleId><ArticleId IdType="pubmed">23372158</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen AK, Lin RY, Hsieh EZ, Tu PH, Chen RP, Liao TY, et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc. 2010;132(4):1186&#x2013;1187. doi: 10.1021/ja9066207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja9066207</ArticleId><ArticleId IdType="pubmed">20055380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Z, Deng J, Zhao W, Yang J. Amyloid-like aggregation and fibril core determination of TDP-43 C-terminal domain. Biochem Biophys Res Commun. 2020;532(4):655&#x2013;661. doi: 10.1016/j.bbrc.2020.08.096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.08.096</ArticleId><ArticleId IdType="pubmed">32907712</ArticleId></ArticleIdList></Reference><Reference><Citation>Babinchak WM, Haider R, Dumm BK, Sarkar P, Surewicz K, Choi JK, et al. The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain. J Biol Chem. 2019;294(16):6306&#x2013;6317. doi: 10.1074/jbc.RA118.007222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.007222</ArticleId><ArticleId IdType="pmc">PMC6484124</ArticleId><ArticleId IdType="pubmed">30814253</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese M, Saal-Bauernschubert L, Luningschror P, Moradi M, Dombert B, Surrey V, et al. Loss of Tdp-43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function. Acta Neuropathol Commun. 2020;8(1):116. doi: 10.1186/s40478-020-00987-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00987-6</ArticleId><ArticleId IdType="pmc">PMC7379803</ArticleId><ArticleId IdType="pubmed">32709255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan R, Humphrey J, Bettencourt C, Newcombe J, Consortium NA, Lashley T, et al. Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions. Acta Neuropathol. 2022;143(3):383&#x2013;401. 10.1007/s00401-021-02399-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34961893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter M, Spiller KJ, Dominique MA, Xu H, Hunter FW, Fang TC, et al. Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery. Acta Neuropathol Commun. 2021;9(1):140. doi: 10.1186/s40478-021-01239-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01239-x</ArticleId><ArticleId IdType="pmc">PMC8377972</ArticleId><ArticleId IdType="pubmed">34412701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano G, Klima R, Feiguin F. TDP-43 prevents retrotransposon activation in the Drosophila motor system through regulation of Dicer-2 activity. BMC Biol. 2020;18(1):82. doi: 10.1186/s12915-020-00816-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-020-00816-1</ArticleId><ArticleId IdType="pmc">PMC7334854</ArticleId><ArticleId IdType="pubmed">32620127</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, et al. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep. 2019;29(5):1164&#x2013;77 e5. 10.1016/j.celrep.2019.09.066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, Priesmann D, Gradus-Pery T, Farberov L, et al. Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun. 2021;12(1):6914. doi: 10.1038/s41467-021-27221-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27221-8</ArticleId><ArticleId IdType="pmc">PMC8617040</ArticleId><ArticleId IdType="pubmed">34824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Birsa N, Bentham MP, Fratta P. Cytoplasmic functions of TDP-43 and FUS and their role in ALS. Semin Cell Dev Biol. 2020;99:193&#x2013;201. doi: 10.1016/j.semcdb.2019.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.05.023</ArticleId><ArticleId IdType="pubmed">31132467</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemenschneider H, Guo Q, Bader J, Frottin F, Farny D, Kleinberger G, et al. Gel-like inclusions of C-terminal fragments of TDP-43 sequester stalled proteasomes in neurons. EMBO Rep. 2022;23(6):e53890. 10.15252/embr.202153890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9171420</ArticleId><ArticleId IdType="pubmed">35438230</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15(1):45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61(5):435&#x2013;445. doi: 10.1002/ana.21154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, et al. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat. 2009;30(11):E974&#x2013;E983. doi: 10.1002/humu.21100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21100</ArticleId><ArticleId IdType="pubmed">19655382</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, Amin H, Kelley T, Shi J, Tian J, Kumaran R, et al. TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. Acta Neuropathol. 2009;118(3):359&#x2013;369. doi: 10.1007/s00401-009-0526-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0526-z</ArticleId><ArticleId IdType="pubmed">19330339</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Zhou Y, Tu L, Ba Z, Huang J, Huang N, et al. TDP-43: From Alzheimer's Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy. Front Mol Neurosci. 2020;13:26. doi: 10.3389/fnmol.2020.00026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00026</ArticleId><ArticleId IdType="pmc">PMC7059763</ArticleId><ArticleId IdType="pubmed">32180703</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, et al. Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathol. 2014;127(3):441&#x2013;450. doi: 10.1007/s00401-013-1211-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1211-9</ArticleId><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40(5):572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#x2013;1527. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol. 2008;67(12):1159&#x2013;1165. doi: 10.1097/NEN.0b013e31818e8951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818e8951</ArticleId><ArticleId IdType="pubmed">19018245</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Barschke P, Otto M. Biomarkers for diseases with TDP-43 pathology. Mol Cell Neurosci. 2019;97:43&#x2013;59. doi: 10.1016/j.mcn.2018.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.10.003</ArticleId><ArticleId IdType="pubmed">30399416</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7(5):409&#x2013;416. doi: 10.1016/S1474-4422(08)70071-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70071-1</ArticleId><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhnlein P, Sperfeld AD, Vanmassenhove B, Van Deerlin V, Lee VM, Trojanowski JQ, et al. Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol. 2008;65(9):1185&#x2013;1189. doi: 10.1001/archneur.65.9.1185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.9.1185</ArticleId><ArticleId IdType="pmc">PMC2742976</ArticleId><ArticleId IdType="pubmed">18779421</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Kaneko K, Yamanaka K. Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J Biol Chem. 2013;288(5):3641&#x2013;3654. doi: 10.1074/jbc.M112.433615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.433615</ArticleId><ArticleId IdType="pmc">PMC3561582</ArticleId><ArticleId IdType="pubmed">23235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Tan W, Whittle C, Qiu L, Cao L, Akbarian S, et al. The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism. PLoS One. 2010;5(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013128</ArticleId><ArticleId IdType="pubmed">21209826</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Kalab P. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD. Neurotherapeutics. 2022 doi: 10.1007/s13311-022-01260-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01260-5</ArticleId><ArticleId IdType="pmc">PMC9587158</ArticleId><ArticleId IdType="pubmed">35790708</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br J Pharmacol. 2021;178(6):1298&#x2013;1315. doi: 10.1111/bph.15148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15148</ArticleId><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori F, Amadio S, Volonte C. Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers. Cell Mol Life Sci. 2021;78(17&#x2013;18):6143&#x2013;6160. doi: 10.1007/s00018-021-03905-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-021-03905-8</ArticleId><ArticleId IdType="pubmed">34322715</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi M, Lee IS, Jantrapirom S, Suda K, Yoshida H. Drosophila models to study causative genes for human rare intractable neurological diseases. Exp Cell Res. 2021;403(1).</Citation><ArticleIdList><ArticleId IdType="pubmed">33812867</ArticleId></ArticleIdList></Reference><Reference><Citation>Appocher C, Mohagheghi F, Cappelli S, Stuani C, Romano M, Feiguin F, et al. Major hnRNP proteins act as general TDP-43 functional modifiers both in Drosophila and human neuronal cells. Nucleic Acids Res. 2017;45(13):8026&#x2013;8045. doi: 10.1093/nar/gkx477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx477</ArticleId><ArticleId IdType="pmc">PMC5570092</ArticleId><ArticleId IdType="pubmed">28575377</ArticleId></ArticleIdList></Reference><Reference><Citation>Azpurua J, El-Karim EG, Tranquille M, Dubnau J. A behavioral screen for mediators of age-dependent TDP-43 neurodegeneration identifies SF2/SRSF1 among a group of potent suppressors in both neurons and glia. PLoS Genet. 2021;17(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8584670</ArticleId><ArticleId IdType="pubmed">34723963</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X, Sun X, Yue W, Duan Y, Hu R, Zhang K, et al. CHMP2B regulates TDP-43 phosphorylation and cytotoxicity independent of autophagy via CK1. J Cell Biol. 2022;221(1). 10.1083/jcb.202103033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8570292</ArticleId><ArticleId IdType="pubmed">34726688</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, et al. Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet. 2014;46(2):152&#x2013;160. doi: 10.1038/ng.2853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2853</ArticleId><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons M, Prieto S, Miguel L, Frebourg T, Campion D, Sune C, et al. Identification of TCERG1 as a new genetic modulator of TDP-43 production in Drosophila. Acta Neuropathol Commun. 2018;6(1):138. doi: 10.1186/s40478-018-0639-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0639-5</ArticleId><ArticleId IdType="pmc">PMC6292132</ArticleId><ArticleId IdType="pubmed">30541625</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Neukomm LJ, Brown RH, Jr, Freeman MR. Age-Dependent TDP-43-Mediated Motor Neuron Degeneration Requires GSK3, hat-trick, and xmas-2. Curr Biol. 2015;25(16):2130&#x2013;2136. doi: 10.1016/j.cub.2015.06.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2015.06.045</ArticleId><ArticleId IdType="pmc">PMC4546534</ArticleId><ArticleId IdType="pubmed">26234214</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan L, Hanson KA, Kim SH, Tare A, Tibbetts RS. Identification of genetic modifiers of TDP-43 neurotoxicity in Drosophila. PLoS One. 2013;8(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584124</ArticleId><ArticleId IdType="pubmed">23468938</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng CW, Lin MJ, Shen CK. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP. J Neurogenet. 2015;29(2&#x2013;3):59&#x2013;68. doi: 10.3109/01677063.2015.1077832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/01677063.2015.1077832</ArticleId><ArticleId IdType="pubmed">26219309</ArticleId></ArticleIdList></Reference><Reference><Citation>Cragnaz L, Spinelli G, De Conti L, Bureau EA, Brownlees J, Feiguin F, et al. Thioridazine reverts the phenotype in cellular and Drosophila models of amyotrophic lateral sclerosis by enhancing TDP-43 aggregate clearance. Neurobiol Dis. 2021;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">34571136</ArticleId></ArticleIdList></Reference><Reference><Citation>Francois-Moutal L, Felemban R, Scott DD, Sayegh MR, Miranda VG, Perez-Miller S, et al. Small Molecule Targeting TDP-43's RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS) ACS Chem Biol. 2019;14(9):2006&#x2013;2013. doi: 10.1021/acschembio.9b00481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.9b00481</ArticleId><ArticleId IdType="pmc">PMC6911355</ArticleId><ArticleId IdType="pubmed">31241884</ArticleId></ArticleIdList></Reference><Reference><Citation>Joardar A, Menzl J, Podolsky TC, Manzo E, Estes PS, Ashford S, et al. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. Hum Mol Genet. 2015;24(6):1741&#x2013;1754. doi: 10.1093/hmg/ddu587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu587</ArticleId><ArticleId IdType="pmc">PMC4381760</ArticleId><ArticleId IdType="pubmed">25432537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollasalehi N, Francois-Moutal L, Scott DD, Tello JA, Williams H, Mahoney B, et al. An Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 Yields Neuroprotective Properties. ACS Chem Biol. 2020;15(11):2854&#x2013;2859. doi: 10.1021/acschembio.0c00494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.0c00494</ArticleId><ArticleId IdType="pmc">PMC8548910</ArticleId><ArticleId IdType="pubmed">33044808</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna S, Esposito S, Masala A, Sini P, Nieddu G, Galioto M, et al. HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo. Cell Death Dis. 2020;11(5):369. doi: 10.1038/s41419-020-2580-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2580-3</ArticleId><ArticleId IdType="pmc">PMC7224392</ArticleId><ArticleId IdType="pubmed">32409664</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118(2):401&#x2013;415. doi: 10.1242/dev.118.2.401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.118.2.401</ArticleId><ArticleId IdType="pubmed">8223268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spradling AC, Rubin GM. Transposition of cloned P elements into Drosophila germ line chromosomes. Science. 1982;218(4570):341&#x2013;347. doi: 10.1126/science.6289435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6289435</ArticleId><ArticleId IdType="pubmed">6289435</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson HM, Preston CR, Phillis RW, Johnson-Schlitz DM, Benz WK, Engels WR. A stable genomic source of P element transposase in Drosophila melanogaster. Genetics. 1988;118(3):461&#x2013;470. doi: 10.1093/genetics/118.3.461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/genetics/118.3.461</ArticleId><ArticleId IdType="pmc">PMC1203300</ArticleId><ArticleId IdType="pubmed">2835286</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterwalder T, Yoon KS, White BH, Keshishian H. A conditional tissue-specific transgene expression system using inducible GAL4. Proc Natl Acad Sci U S A. 2001;98(22):12596&#x2013;12601. doi: 10.1073/pnas.221303298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.221303298</ArticleId><ArticleId IdType="pmc">PMC60099</ArticleId><ArticleId IdType="pubmed">11675495</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks DS, Vishal K, Kawakami J, Bouyain S, Geisbrecht ER. Optimization of wrMTrck to monitor Drosophila larval locomotor activity. J Insect Physiol. 2016;93&#x2013;94:11&#x2013;17. doi: 10.1016/j.jinsphys.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinsphys.2016.07.007</ArticleId><ArticleId IdType="pmc">PMC5722213</ArticleId><ArticleId IdType="pubmed">27430166</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantrapirom S, Enomoto Y, Karinchai J, Yamaguchi M, Yoshida H, Fukusaki E, et al. The depletion of ubiquilin in Drosophila melanogaster disturbs neurochemical regulation to drive activity and behavioral deficits. Sci Rep. 2020;10(1):5689. doi: 10.1038/s41598-020-62520-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62520-y</ArticleId><ArticleId IdType="pmc">PMC7105486</ArticleId><ArticleId IdType="pubmed">32231214</ArticleId></ArticleIdList></Reference><Reference><Citation>Jantrapirom S, Lo Piccolo L, Yoshida H, Yamaguchi M. A new Drosophila model of Ubiquilin knockdown shows the effect of impaired proteostasis on locomotive and learning abilities. Exp Cell Res. 2018;362(2):461&#x2013;471. doi: 10.1016/j.yexcr.2017.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2017.12.010</ArticleId><ArticleId IdType="pubmed">29247619</ArticleId></ArticleIdList></Reference><Reference><Citation>Cragnaz L, Klima R, Skoko N, Budini M, Feiguin F, Baralle FE. Aggregate formation prevents dTDP-43 neurotoxicity in the Drosophila melanogaster eye. Neurobiol Dis. 2014;71:74&#x2013;80. doi: 10.1016/j.nbd.2014.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.07.009</ArticleId><ArticleId IdType="pubmed">25088712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Piccolo L, Bonaccorso R, Onorati MC. Nuclear and Cytoplasmic Soluble Proteins Extraction from a Small Quantity of Drosophila's Whole Larvae and Tissues. Int J Mol Sci. 2015;16(6):12360&#x2013;12367. doi: 10.3390/ijms160612360.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms160612360</ArticleId><ArticleId IdType="pmc">PMC4490448</ArticleId><ArticleId IdType="pubmed">26039237</ArticleId></ArticleIdList></Reference><Reference><Citation>Langellotti S, Romano V, Romano G, Klima R, Feiguin F, Cragnaz L, et al. A novel Drosophila model of TDP-43 proteinopathies: N-terminal sequences combined with the Q/N domain induce protein functional loss and locomotion defects. Dis Model Mech. 2016;9(6):659&#x2013;669. doi: 10.1242/dmm.023382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.023382</ArticleId><ArticleId IdType="pmc">PMC4920146</ArticleId><ArticleId IdType="pubmed">27101846</ArticleId></ArticleIdList></Reference><Reference><Citation>Potenza RL, De Simone R, Armida M, Mazziotti V, Pezzola A, Popoli P, et al. Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2016;13(4):918&#x2013;927. doi: 10.1007/s13311-016-0462-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0462-2</ArticleId><ArticleId IdType="pmc">PMC5081121</ArticleId><ArticleId IdType="pubmed">27456702</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, et al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017;56(6):1077&#x2013;1084. doi: 10.1002/mus.25733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25733</ArticleId><ArticleId IdType="pmc">PMC5724488</ArticleId><ArticleId IdType="pubmed">28662296</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Ikuta T, Kawakami K, Kise R, Qian Y, Xia R, et al. Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism. Nat Chem Biol. 2022;18(3):281&#x2013;288. doi: 10.1038/s41589-021-00930-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-021-00930-3</ArticleId><ArticleId IdType="pubmed">34937912</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh SK, Kordula T, Spiegel S. Neuronal contact upregulates astrocytic sphingosine-1-phosphate receptor 1 to coordinate astrocyte-neuron cross communication. Glia. 2022;70(4):712&#x2013;727. doi: 10.1002/glia.24135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.24135</ArticleId><ArticleId IdType="pmc">PMC9219554</ArticleId><ArticleId IdType="pubmed">34958493</ArticleId></ArticleIdList></Reference><Reference><Citation>Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013;5(1):105&#x2013;121. doi: 10.1002/emmm.201201283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201283</ArticleId><ArticleId IdType="pmc">PMC3569657</ArticleId><ArticleId IdType="pubmed">23180565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hait NC, Wise LE, Allegood JC, O'Brien M, Avni D, Reeves TM, et al. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci. 2014;17(7):971&#x2013;980. doi: 10.1038/nn.3728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3728</ArticleId><ArticleId IdType="pmc">PMC4256678</ArticleId><ArticleId IdType="pubmed">24859201</ArticleId></ArticleIdList></Reference><Reference><Citation>Leo A, Citraro R, Amodio N, De Sarro C, Gallo Cantafio ME, Constanti A, et al. Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model. Neurotherapeutics. 2017;14(4):1134&#x2013;1147. doi: 10.1007/s13311-017-0550-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-017-0550-y</ArticleId><ArticleId IdType="pmc">PMC5722759</ArticleId><ArticleId IdType="pubmed">28653281</ArticleId></ArticleIdList></Reference><Reference><Citation>Herr DR, Fyrst H, Creason MB, Phan VH, Saba JD, Harris GL. Characterization of the Drosophila sphingosine kinases and requirement for Sk2 in normal reproductive function. J Biol Chem. 2004;279(13):12685&#x2013;12694. doi: 10.1074/jbc.M310647200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M310647200</ArticleId><ArticleId IdType="pubmed">14722126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hait NC, Avni D, Yamada A, Nagahashi M, Aoyagi T, Aoki H, et al. The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERalpha expression and enhances hormonal therapy for breast cancer. Oncogenesis. 2015;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4753524</ArticleId><ArticleId IdType="pubmed">26053034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemian M, Ghasemi-Kasman M, Parsian H, Sadeghi F. Fingolimod (FTY720) improves the functional recovery and myelin preservation of the optic pathway in focal demyelination model of rat optic chiasm. Brain Res Bull. 2019;153:109&#x2013;121. doi: 10.1016/j.brainresbull.2019.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2019.08.014</ArticleId><ArticleId IdType="pubmed">31442591</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CC, Jin LW, Wang IF, Wei WY, Ho PC, Liu YC, et al. HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies. EMBO Mol Med. 2020;12(6):e10622. 10.15252/emmm.201910622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278561</ArticleId><ArticleId IdType="pubmed">32449313</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo K, Wang Z, Zhuang K, Yuan S, Liu F, Liu A. Suberoylanilide hydroxamic acid suppresses axonal damage and neurological dysfunction after subarachnoid hemorrhage via the HDAC1/HSP70/TDP-43 axis. Exp Mol Med. 2022 doi: 10.1038/s12276-022-00761-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00761-9</ArticleId><ArticleId IdType="pmc">PMC9535006</ArticleId><ArticleId IdType="pubmed">35501375</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>